Last update Jan. 12, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
1-Benzhydryl-4-methylpiperazine belongs to this group or family:
Main tradenames from several countries containing 1-Benzhydryl-4-methylpiperazine in its composition:
Variable | Value | Unit |
---|---|---|
Molecular weight | 266 | daltons |
VD | 23 (12-30) | l/Kg |
T½ | 13 (7-48) | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Cyclizine is a first generation antihistamine and antiemetic drug derived from piperazine used for the prevention and treatment of nausea, vomiting and dizziness associated with motion sickness and vertigo and in Ménière's vertigo. Moderate sedative effect. Oral administration up to three times a day.
At the time of the last update, we found no published data on its excretion in breast milk.
The scarce pharmacokinetic data published do not allow predicting its possible excretion in breast milk, although some authors consider it moderate. (Solhaug 2004)
Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. (Nice 2000)